GPR 120: The Potential Target for Obesity Treatment

Author(s): Peter A. Tanagho, Kyrillus S. Shohdy

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders

Volume 16 , Issue 1 , 2016

Become EABM
Become Reviewer
Call for Editor


Background: G protein coupled receptor 120 (GPR120) is a class of receptors in the gastrointestinal tract (GIT) that is implicated in nutrient sensing and body weight regulation. Functions of GPR120 are thought to be mediated by the release of a group of hormones known as incretins, such as glucagon like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP).

Methods: We have searched PubMed with the keywords "GPR120","GLP-1" and "obesity". Relevant studies were retrieved and included in the review.

Results: Recently, many exogenous compounds have been investigated in their role in the release of GLP-1 and in causing weight loss in obese rats. However, some results question the putative role of GPR120 in metabolic homeostasis.

Conclusion: Herein, we evaluate the potential use of GPR120 as a target receptor in obesity and found it to be ubiquitous throughout the GIT, with various functions in each site. In order to find the optimal drug, the role of GPR120 in each site needs to be defined and selectivity of the potential drug needs to be studied to ensure the success of this growing line of obesity management.

Keywords: Fecal microbiota, GLP-1, GPR120, obesity, treatment.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Page: [8 - 11]
Pages: 4
DOI: 10.2174/1871530316666151123115611
Price: $65

Article Metrics

PDF: 55